澳大利亚和新西兰单胚胎移植后单绒毛膜双羊膜囊双胎的发病率及危险因素:154 671例活产分析
该回顾性队列研究分析澳大利亚和新西兰2009年至2021年590 441个自体单胚胎移植周期中的154 671例活产,单绒毛膜双羊膜囊双胎发生率为1.5%。囊胚移植较卵裂期移植增加约2倍风险(aOR=1.99,95%CI 1.71-2.31),玻璃化复苏移植较新鲜移植风险更低(aOR=0.87,95%CI 0.79-0.95)。
要点
- 单胚胎移植后活产中单绒毛膜双羊膜囊双胎发生率为1.5%。
- 囊胚移植较卵裂期移植单绒毛膜双羊膜囊双胎风险约增2倍(aOR=1.99)。
- 玻璃化复苏移植较新鲜移植单绒毛膜双羊膜囊双胎风险更低(aOR=0.87)。
核心结论
- 在澳大利亚和新西兰的单胚胎移植活产中,单绒毛膜双羊膜囊双胎发生率为1.5%,囊胚移植和新鲜胚胎移植是单绒毛膜双羊膜囊双胎的关键危险因素,玻璃化复苏移植与较低风险相关。
研究设计与样本
- 回顾性队列研究,分析澳大利亚和新西兰2009年至2021年间590 441个单胚胎移植周期,纳入澳大利亚和新西兰辅助生殖技术数据库(ANZARD)中154 671例自体单胚胎移植活产。
主要发现
- 单胚胎移植活产中单绒毛膜双羊膜囊双胎发生率为1.5%。
- 囊胚移植较卵裂期移植的单绒毛膜双羊膜囊双胎风险约增加2倍(aOR=1.99,95%CI 1.71-2.31)。
- 玻璃化复苏移植较新鲜移植的单绒毛膜双羊膜囊双胎风险更低(aOR=0.87,95%CI 0.79-0.95)。
- 敏感性分析支持上述发现,按母亲年龄、受精技术和胚胎移植类型(新鲜/冷冻)分组的亚组中单绒毛膜双羊膜囊双胎风险模式一致。
临床怎么用
- 该研究将囊胚移植和新鲜胚胎移植识别为辅助生殖技术中单绒毛膜双羊膜囊双胎的重要危险因素,对患者咨询和产科保健具有潜在意义。
- 作者认为未来研究应进一步探究这些关联的机制。
局限性
- 卵裂性估计基于Weinberg差别规则而非DNA检测,可能导致一些错分。
- 研究缺乏胚胎质量数据,该变量可能影响单绒毛膜双羊膜囊双胎风险。
- 研究为回顾性设计,可能引入治疗偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the incidence of and risk factors for monozygotic twinning (MZT) following single embryo transfer (SET) in ART cycles in Australia and New Zealand? SUMMARY ANSWER: MZT occurred in 1.5% of live births following SET, with blastocyst transfer and fresh embryo transfer identified as key risk factors, while vitrified-thaw transfers were associated with a lower MZT risk. WHAT IS KNOWN ALREADY: ART has been associated with a higher incidence of MZT compared to natural conception. Previous studies have suggested younger maternal age, blastocyst culture, fresh embryo transfer, and certain ART techniques, such as assisted hatching and preimplantation genetic testing may elevate MZT risk. However, findings have been inconsistent, and with many prior studies underpowered and few reflecting contemporary ART practices. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study analyzed data from 590 441 SET cycles conducted between 2009 and 2021 in Australia and New Zealand. The analysis included 154 671 live births following autologous SET cycles recorded in the Australian and New Zealand Assisted Reproductive Technology Database (ANZARD). PARTICIPANTS/MATERIALS, SETTING, METHODS: The study focused on autologous fresh and thawed SET cycles. MZT incidence was estimated by applying Weinberg's differential rule, which assumes a 1:1 ratio of sex-concordant and sex-discordant dizygotic twins in the population of twins born following SET cycles. A multivariable logistic regression model with generalized estimating equations was used to identify risk factors for MZT, adjusting for potential misclassification of zygosity due to the absence of DNA confirmation. MAIN RESULTS AND THE ROLE OF CHANCE: The MZT rate was 1.5% among live births following SET. Blastocyst transfer was associated with a nearly 2-fold increase in MZT risk compared to cleavage-stage transfer (adjusted odds ratio [aOR] = 1.99, 95% CI: 1.71-2.31), and vitrified-thaw transfers had a lower MZT risk than fresh transfers (aOR = 0.87, 95% CI: 0.79-0.95). Sensitivity analyses supported these findings, with consistent MZT risk patterns across subgroups by maternal age, fertilization technique, and embryo transfer type (fresh/frozen). LIMITATIONS, REASONS FOR CAUTION: Zygosity estimation was based on Weinberg's differential rule rather than DNA testing, which could lead to some misclassification. Additionally, the study lacked data on embryo quality, a variable with potential influence on MZT risk, and was limited to a retrospective design, potentially introducing treatment and information biases. WIDER IMPLICATIONS OF THE FINDINGS: This large-scale study identifies blastocyst transfer and fresh embryo transfer as significant MZT risk factor in ART, with potential implications for patient counseling and obstetric care. Future research should further investigate the mechanisms underlying these associations. STUDY FUNDING/COMPETING INTEREST(S): Funding was received from the Ferring Pharmaceuticals Pty Ltd as part of the Ferring FSANZ Leaders in Fertility Research and Education grant (to R.C.P.). The sponsors had no role in the design and conduct of the study; data collection, management, analysis, and interpretation; manuscript preparation, review, or approval; or the decision to submit for publication. FSANZ contracts National Perinatal Epidemiology and Statistics Unit (NPESU) of the University of New South Wales (UNSW) to prepare annual reports and benchmarking reports from the ANZARD: one of those datasets is used in this study. R.C.P. is a Research Fellow of the NPESU, UNSW; C.A.V. is affiliated with the NPESU, UNSW; G.M.C. is an employee of the UNSW and is the Director of the NPESU, UNSW. C.A.V., based at Aristotle University of Thessaloniki (Greece), is a member of the Executive Board of the Hellenic Society of Fertility and Sterility and serves as Senior Deputy of the Steering Committee for the SIG Reproductive Endocrinology of ESHRE. C.A.V. also reports lecture and advisory roles from Merck Ltd, Merck Sharpe & Dohme, Ferring, Organon, Gedeon-Richter, IBSA, Vianex, and Sonapharm; travel support from Merck Ltd, Merck Sharpe & Dohme, Ferring, Organon, Gedeon-Richter, and Vianex; and holds stock or stock options in Virtus Health Ltd, all outside the submitted work. O.F. reports funding from Ferring Pharmaceuticals Pty Ltd, unrelated to this study. TRIAL REGISTRATION NUMBER: N/A.
引用
- Paul RC, Venetis CA, Fitzgerald O, et al. Incidence and risk factors of monozygotic twinning following ART: analysis of 154 671 live births resulting from single embryo transfer. Hum Reprod. 2025. PMID: 40587819. doi:10.1093/humrep/deaf121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。